Pharsight

Dayvigo generic

Dayvigo is an insomnia treatment drug owned by Eisai Inc. The drug, containing the active ingredient lemborexant, received its first market authorization on 07 April 2020.

When will Dayvigo generic be available?

Dayvigo generic is expected to become available after 21 October, 2035. This date corresponds to the expiration of the last patent held for the drug. Drug patent challenges can start to be filed against Dayvigo from 7th April 2024.

Dayvigo uses

Dayvigo is used in the treatment of adult patients suffering from insomnia, which is characterized by difficulties with sleep onset and/or sleep maintenance. The drug leverages lemborexant to effectively address these issues.

Dayvigo patent expiration

Dayvigo has two patents in effect. The final patent, titled 'Compositions and methods for treating insomnia', is set to expire on 21 October, 2035. This date indicates when the Dayvigo generic could potentially be made available. Below are the details of the patent:

Dayvigo dosage

Want to ask something?